

---

11. (Amended) The method of claim 1 wherein said BCG is formulated with a keratolytic agent for topical application to the area of infection.

B4 12. (Amended) The method of claim 11 wherein said BCG is formulated with said keratolytic agent as a cream for adherent application to the area of infection.

13. (Amended) The method of claim 1 wherein said BCG is formulated with powdered salicylic acid as an adherent cream for application to the area of infection.

---

15. (Amended) The method of claim 14 wherein said salicylic acid is present in an amount of about 1 to about 10 wt% of the composition.

B5 16. (Amended) A therapeutic composition for the treatment of a disease condition caused by papilloma virus, comprising a treatment dose of Bacillus Calmette-Guerin (BCG) formulated with a keratolytic agent for topical application to an area of infection.

---

B6 20. (Amended) The composition of claim 16 wherein said keratolytic agent is powdered salicylic acid.

B7 22. (Amended) The composition of claim 21 wherein said salicylic acid is present in an amount of about 1 to about 10 wt% of the composition.

---

Cancel claims 5 to 7, 17 to 19, 24 and 25.